Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma. - Wikidata - awgldk - TriplyDB

Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.

Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.

http://www.wikidata.org/entity/Q38753582

about

Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations.Clinical trials of tyrosine kinase inhibitors for lung cancer in China: a review A novel multi-target inhibitor harboring selectivity of inhibiting EGFR T790M sparing wild-type EGFR.Understanding and targeting resistance mechanisms in NSCLC.In vitro and in vivo anti-tumor activity of alectinib in tumor cells with NCOA4-RET.Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.Non-mammalian models of multiple endocrine neoplasia type 2.The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling.Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer.MiR-21 improves invasion and migration of drug-resistant lung adenocarcinoma cancer cell and transformation of EMT through targeting HBP1.Emerging application of genomics-guided therapeutics in personalized lung cancer treatment.Drug resistance profiles of mutations in the RET kinase domain Personalized therapy for lung cancer: Striking a moving target

P2860

Q38724603-3B0C7F88-A366-41CD-B596-31D3EF8878A2 Q41292062-7D7AB1B3-D84A-424C-A70A-C7AB2B8952D6 Q42367902-AA50EC87-0B66-40FD-9F8F-D4DB02655684 Q46915997-6A966BBE-ADF6-4C66-A28E-4DA0C166B704 Q47104655-6FD4F418-BA08-4419-87B1-8D8CE313D48F Q47601932-68251BFD-31B2-4D71-87F6-852483AA28F1 Q47724734-BDE4C109-461A-48C6-84F5-B8511FDA22FE Q50085302-E44BCE39-A403-4301-9F05-4483FB8F032E Q51004850-2694CDB3-E50C-4A34-B6E0-85FDD0681678 Q52312436-6995B82C-DD22-49BA-8667-37344B939BDF Q53694673-81358AB3-F539-4DC4-8E40-4E470C93D793 Q55314894-DDBA518B-8245-44AB-BC2C-3C296551750E Q58044610-9A37C6F1-90ED-40F5-8F0B-98CAE6717F91 Q58792324-0C5C1E90-B1DE-4BA6-806E-250A11F92819

P2860

Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.

http://www.wikidata.org/entity/Q38753582

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.

@en

type

label

Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.

@en

prefLabel

Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.

@en

P1433

Q38753582-0802097B-DD6B-4CDB-9BB9-FE8888CECB48

P1476

Q38753582-14B52763-26CC-4F4F-B529-12313BBF431D

P2093

Q38753582-01E3547F-B33C-4CDA-9F56-27C16DA91AF5

Q38753582-0C7C9E05-10D2-43ED-9F43-33F2EC7463AA

Q38753582-10723F12-C3DD-4FB1-80CB-934E420545BC

Q38753582-47A91853-3C41-4367-B972-12DCFBD40E58

Q38753582-4DE68C7D-4ADF-4715-8BE7-703EBB1C1534

Q38753582-7C83B9D1-1B42-443C-BC9A-607783FC7211

Q38753582-88438A86-44B7-4C65-9343-5B26989146CA

Q38753582-9DC5683C-FF7D-4147-BE68-175562A58BCF

Q38753582-A3A39C28-7794-4615-A85B-93AF70EB1F4D

Q38753582-B92CA01E-00F6-4C6C-B35B-EBADC59023CB

P2860

Q38753582-091F833F-7CD7-4ECA-9981-7E7FB7B40278

Q38753582-0F0BD86F-1702-42B3-8D0F-DF328F3285A3

Q38753582-1571DB1B-BF88-42EA-996C-0EB0A1D1CA6F

Q38753582-15A75367-9092-4888-B10C-934880840FAF

Q38753582-1A2669C8-5B70-46FB-AF98-36993B621D3F

Q38753582-1BB42D70-E7B6-4A69-880C-776994E3C648

Q38753582-240FD802-928A-42F8-B666-7E97F10B3369

Q38753582-2830BC00-8DD6-42CD-86DD-C8447324E681

Q38753582-38951393-84A8-451D-88CC-9A3F70DFBBB9

Q38753582-3A4EC86A-072F-45BE-9911-C9FB57826687

P304

Q38753582-356350F3-5423-45AC-A5BE-9843C9EE5320

P31

Q38753582-06CF87C9-36E9-4481-B921-642FEFBF701D

P356

Q38753582-395D65F1-95D8-4B1F-9907-DB157301A385

P433

Q38753582-6765E9F2-73F1-4CE2-82F8-79F49C802F7B

P478

Q38753582-94F7670F-3D44-411E-B6AE-B77B50174B64

P50

Q38753582-BC3198DD-BEC4-4EAF-A3D1-577B56FB237A

P577

Q38753582-2FFD5359-0DCA-46AB-9757-903A0F264BA2

P698

Q38753582-85AB6B8A-6D16-4D28-97DE-B055F4D43E3B

P921

Q38753582-1DAFE691-2DBF-4B7E-BCA7-6C1B31571CC8

P932

Q38753582-FDBDAF0A-2C30-4394-BA33-2C7B20C9BC7A

P356

1535-7163.MCT-16-0258

P1433

Molecular Cancer Therapeutics

P1476

Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.

@en

P2093

Chengliu Jin

http://www.w3.org/2001/XMLSchema#string

Eric B Haura

http://www.w3.org/2001/XMLSchema#string

Gary V Martinez

http://www.w3.org/2001/XMLSchema#string

Jie Wu

http://www.w3.org/2001/XMLSchema#string

Kar-Ming Fung

http://www.w3.org/2001/XMLSchema#string

Lichao Zhao

http://www.w3.org/2001/XMLSchema#string

Mikalai M Budzevich

http://www.w3.org/2001/XMLSchema#string

Noreen Luetteke

http://www.w3.org/2001/XMLSchema#string

Qingling Huang

http://www.w3.org/2001/XMLSchema#string

Rikesh J Makanji

http://www.w3.org/2001/XMLSchema#string

P2860

Roles of Gab1 and SHP2 in paxillin tyrosine dephosphorylation and Src activation in response to epidermal growth factor

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.

A patient with lung adenocarcinoma and RET fusion treated with vandetanib.

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Comprehensive molecular profiling of lung adenocarcinoma.

RET fusion gene: translation to personalized lung cancer therapy

P304

2521-2529

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-16-0258

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Domenico Coppola

P577

2016-08-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27496134

http://www.w3.org/2001/XMLSchema#string

P921

P932

5289739

http://www.w3.org/2001/XMLSchema#string